1. Home
  2. PRE vs IFRX Comparison

PRE vs IFRX Comparison

Compare PRE & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prenetics Global Limited

PRE

Prenetics Global Limited

N/A

Current Price

$25.43

Market Cap

301.5M

Sector

Industrials

ML Signal

N/A

Logo InflaRx N.V.

IFRX

InflaRx N.V.

N/A

Current Price

$2.21

Market Cap

303.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRE
IFRX
Founded
2014
2007
Country
Hong Kong
Germany
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
301.5M
303.4M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
PRE
IFRX
Price
$25.43
$2.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$30.50
$6.25
AVG Volume (30 Days)
260.7K
960.7K
Earning Date
06-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$108.69
N/A
Revenue Next Year
$58.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.29
$0.80
52 Week High
$27.24
$2.95

Technical Indicators

Market Signals
Indicator
PRE
IFRX
Relative Strength Index (RSI) 67.91 55.74
Support Level $17.49 $0.87
Resistance Level N/A $2.57
Average True Range (ATR) 1.74 0.17
MACD 0.51 0.00
Stochastic Oscillator 83.23 42.42

Price Performance

Historical Comparison
PRE
IFRX

About PRE Prenetics Global Limited

Prenetics Global Ltd is a consumer health and wellness company offering nutrition and longevity products through its flagship brand, IM8. It offers science-backed daily nutrition and longevity products distributed directly to consumers across multiple countries. The company's products are developed with scientific input and are subject to third-party quality certifications.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: